In August 2015, she started a career as a clinician scientist at the Department of Radiation Oncology, Klinikum rechts der Isar. Through various research funding programs, she established the basis of her research focus “Personalized RadioOncology of pancreatic cancer”, and set up a junior research group.

Thematically and methodologically, she could build on her experimental thesis in the field of targeted nanoparticles for improved imaging and therapy in pancreatic cancer at the European Pancreatic Cancer Center Heidelberg.

As a clinician scientist, she aims to combine clinical activities and scientific projects, develop novel ideas and concepts, and work on translation from the lab to the clinic, as well as clinical questions from the clinic in the lab. With these translational approaches, she is closely involved in SFB 1321, the German Consortium for Translational Cancer Research (DKTK), and the working group young DEGRO of the society of radiation oncology.

In addition, her profile is completed by intercultural competencies from several stays abroad in Japan, Great Britain, India, and Nepal.

Her research focuses on mechanisms of radioresistance of pancreatic cancer. The treatment of pancreatic cancer, one of the most aggressive and lethal human tumors, is still an unsolved health problem. The poor survival can be attributed to a high genetic heterogeneity leading to therapeutic resistance. Therefore, individualized high-precision radiation concepts in combination with cytotoxic agents, targeted therapies, or herbal substances are new therapeutic approaches for pancreatic cancer.

The major goal of the research is to overcome the radioresistance of pancreatic cancer and thereby pave the way to novel effective treatments and improve the clinical outcome of patients with pancreatic cancer.